|
gptkbp:instanceOf
|
opioid medication
|
|
gptkbp:activeDuring
|
oxycodone
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:OxyContin
|
|
gptkbp:chemicalFormula
|
C18H21NO4
|
|
gptkbp:claims
|
numerous
|
|
gptkbp:consequences
|
high
|
|
gptkbp:contraindication
|
severe asthma
intestinal obstruction
hypersensitivity to oxycodone
|
|
gptkbp:convictedOf
|
yes
|
|
gptkbp:dependency
|
high
|
|
gptkbp:diseaseResistance
|
possible
|
|
gptkbp:dosageForm
|
10 mg
extended-release tablet
20 mg
160 mg
80 mg
40 mg
|
|
gptkbp:drugInterdiction
|
high
available
|
|
gptkbp:duration
|
12 hours
|
|
gptkbp:endOfLife
|
3 to 6 hours
|
|
gptkbp:formFactor
|
tablet
|
|
gptkbp:healthcare
|
important
required
|
|
gptkbp:history
|
controversial
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OxyContin
|
|
gptkbp:impact
|
chronic pain
opioid crisis
acute_pain
|
|
gptkbp:inheritsFrom
|
1 hour
|
|
gptkbp:interactsWith
|
alcohol
antidepressants
benzodiazepines
muscle relaxants
|
|
gptkbp:lastProduced
|
1995
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Purdue_Pharma
|
|
gptkbp:marketedAs
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:notableFeature
|
gptkb:Opana
gptkb:Roxicodone
Percocet
|
|
gptkbp:packaging
|
bottle
|
|
gptkbp:providesGuidelinesFor
|
followed
|
|
gptkbp:providesSupportFor
|
II
|
|
gptkbp:publicPerception
|
negative
|
|
gptkbp:reform
|
2010
|
|
gptkbp:riskManagement
|
yes
|
|
gptkbp:route
|
oral
|
|
gptkbp:sideEffect
|
dizziness
nausea
drowsiness
constipation
|
|
gptkbp:symptoms
|
yes
|
|
gptkbp:type
|
oxycodone hydrochloride
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:weight
|
315.4 g/mol
|